



ASX ANNOUNCEMENT

Cann Group Receives \$836k Funding Advance on R&D Refund

28 April 2025 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) announced today that it has entered into an agreement for an advance of \$836,469 (**Advance**) from Radium Capital (**Radium**), providing early access to the Company's expected Research and Development (R&D) Tax Incentive for FY2025, associated with R&D activities conducted up until the end of February 2025 (**R&D Refund**).

The Advance is to be provided under the terms of a loan agreement executed between Cann and Radium (the **Loan Facility**). The Advance incurs an interest rate of 15.0% per annum, calculated daily which will be repaid on the date that proceeds of the R&D Refund are received, or 31 October 2025 (whichever occurs earlier).

Jenni Pilcher, CEO & Managing Director states: "The Advance will support Cann's strategy of supplying the medicinal cannabis market with unique products developed through the R&D activities of the Company. This includes products sold under the Company's Botanitech brand throughout Australia, including via the newly established collaboration with Chemist Warehouse outlets."

Authorised for release by Steven Notaro, Company Secretary, Cann Group Limited.

For all other information please contact:

Jenni Pilcher
CEO & Managing Director
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Steven Notaro
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com